Brain-Derived Neurotrophic Factor (BDNF) is the most abundant neurotrophin in the central nervous system (CNS) and plays critical roles in neuronal survival, synaptic plasticity, neurogenesis, and cognitive function. BDNF is a member of the neurotrophin family, which also includes nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). The BDNF-TrkB signaling axis represents a major therapeutic target for neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease (HD)[@bdnf_ad_2014].
BDNF is synthesized as a precursor protein called pro-BDNF, which can be proteolytically cleaved to generate mature BDNF. This dual nature of BDNF is critically important for understanding its functions: mature BDNF signals through the TrkB receptor to promote neuronal survival and synaptic plasticity, while pro-BDNF signals through the p75NTR receptor to promote apoptosis and synaptic pruning during development and in disease states[@probdnf_p75_2011].
The importance of BDNF in neurodegeneration cannot be overstated. BDNF levels are reduced in affected brain regions in virtually every major neurodegenerative disease, and experimental BDNF delivery shows neuroprotective effects in multiple animal models. However, translating these findings to the clinic has proven challenging due to the difficulty of delivering BDNF to the CNS and the complex signaling dynamics of the BDNF system.
Brain-Derived Neurotrophic Factor (BDNF) is the most abundant neurotrophin in the central nervous system (CNS) and plays critical roles in neuronal survival, synaptic plasticity, neurogenesis, and cognitive function. BDNF is a member of the neurotrophin family, which also includes nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). The BDNF-TrkB signaling axis represents a major therapeutic target for neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease (HD)[@bdnf_ad_2014].
BDNF is synthesized as a precursor protein called pro-BDNF, which can be proteolytically cleaved to generate mature BDNF. This dual nature of BDNF is critically important for understanding its functions: mature BDNF signals through the TrkB receptor to promote neuronal survival and synaptic plasticity, while pro-BDNF signals through the p75NTR receptor to promote apoptosis and synaptic pruning during development and in disease states[@probdnf_p75_2011].
The importance of BDNF in neurodegeneration cannot be overstated. BDNF levels are reduced in affected brain regions in virtually every major neurodegenerative disease, and experimental BDNF delivery shows neuroprotective effects in multiple animal models. However, translating these findings to the clinic has proven challenging due to the difficulty of delivering BDNF to the CNS and the complex signaling dynamics of the BDNF system.
> Key insight: The balance between pro-BDNF and mature BDNF, and the relative activity of TrkB versus p75NTR signaling, represents a critical determinant of neuronal fate in neurodegeneration. Therapeutic strategies that shift this balance toward TrkB signaling may provide neuroprotection.
BDNF is synthesized in the endoplasmic reticulum as a precursor pre-pro-BDNF molecule. The pre-sequence targets BDNF for secretion, while the pro-domain contains a cleavage site for proteolytic processing. Two primary proteases are responsible for converting pro-BDNF to mature BDNF: tissue-type plasminogen activator (tPA) and plasmin[@trkb_mech_2012].
The conversion of pro-BDNF to mature BDNF is activity-dependent, occurring preferentially at active synapses. Neuronal activity triggers calcium influx through NMDA receptors and voltage-gated calcium channels, which activates tPA and plasminogen, leading to pro-BDNF cleavage. This activity-dependent processing ensures that BDNF signaling is spatially and temporally regulated in response to synaptic activity.
The pro-BDNF molecule itself is biologically active and serves as the ligand for the p75NTR receptor. The pro-domain of BDNF has been shown to have distinct biological activities, including regulation of neuronal migration and synaptic plasticity. Understanding the regulation of pro-BDNF versus mature BDNF production is crucial for developing therapeutic interventions.
The TrkB (Tropomyosin receptor kinase B) receptor is a tyrosine kinase receptor that mediates the pro-survival and plasticity-promoting effects of mature BDNF. TrkB exists in multiple isoforms: the full-length TrkB (TrkB-FL) with intrinsic tyrosine kinase activity, and truncated isoforms (TrkB-T1, TrkB-T2) that act as dominant-negative regulators.
Upon BDNF binding, TrkB dimerizes and undergoes autophosphorylation at multiple tyrosine residues. This activation triggers three major downstream signaling pathways that mediate distinct cellular responses[@trkb_mech_2012]:
PI3K/Akt Pathway: Phosphorylated TrkB recruits PI3K through its SH2 domains, leading to Akt activation. Akt phosphorylates multiple targets that promote survival, including FOXO transcription factors, Bad, and caspase-9. The PI3K/Akt pathway also activates mTOR, driving protein synthesis necessary for synaptic plasticity[@mtor_bdnf_2016].
PLCγ Pathway: TrkB activates phospholipase C-gamma (PLCγ), which hydrolyzes PIP2 to generate IP3 and DAG. IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C (PKC). This pathway regulates synaptic transmission, dendritic spine morphology, and gene expression.
MAPK/ERK Pathway: Ras activation downstream of TrkB triggers the MAPK cascade, leading to ERK1/2 activation. ERK phosphorylates multiple targets including transcription factors (CREB, Elk-1), ribosomal S6 kinase (RSK), and MAP kinase-interacting kinases (MNKs). This pathway promotes neuronal differentiation, gene expression, and synaptic plasticity.
The p75 neurotrophin receptor (p75NTR) is a member of the tumor necrosis factor receptor superfamily and can bind all neurotrophins with different affinities. p75NTR has the highest affinity for pro-BDNF and NGF, making it a key receptor for pro-neurotrophin signaling[@probdnf_p75_2011].
p75NTR signaling is complex and context-dependent, capable of triggering both pro-survival and pro-apoptotic responses. The outcome depends on the cellular context, available co-receptors, and the specific ligand.
Pro-survival signaling: When co-expressed with Trk receptors, p75NTR can enhance Trk signaling through multiple mechanisms. p75NTR can act as a co-receptor, increasing ligand affinity for Trk. Additionally, p75NTR activates NF-κB signaling, which promotes cell survival.
Pro-apoptotic signaling: In the absence of Trk receptors or when bound by pro-neurotrophins, p75NTR can trigger apoptosis through the NRIF (NRF) pathway and JNK activation. This function is particularly important during development for proper neuronal pruning, but becomes pathological in neurodegeneration when pro-BDNF accumulates.
Alzheimer's disease is characterized by multiple alterations in BDNF signaling that contribute to synaptic dysfunction and neuronal loss. These changes create a vicious cycle where synaptic loss reduces BDNF production, which in turn impairs the synaptic plasticity necessary for cognitive function[@bdnf_ad_2014].
BDNF reduction: Post-mortem studies consistently show decreased BDNF protein and mRNA levels in the hippocampus and cortex of AD brains. The extent of BDNF reduction correlates with cognitive decline and neuropathological severity. This reduction likely reflects the loss of synaptic connections, as BDNF is produced in an activity-dependent manner.
TrkB impairment: Amyloid-beta (Aβ) oligomers directly impair TrkB signaling through multiple mechanisms. Aβ oligomers bind to TrkB and prevent its proper dimerization and activation. Additionally, Aβ promotes the accumulation of TrkB in endosomes, impairing its trafficking to the cell surface[@abeta_trkb_2013].
Pro-BDNF accumulation: Evidence suggests that pro-BDNF accumulates in AD brains due to altered protease activity and increased production. Pro-BDNF signaling through p75NTR promotes apoptosis and synaptic elimination, contributing to disease progression[@pro_bdnf_ad_2014].
Axonal transport defects: BDNF is anterogradely transported from the cortex to the hippocampus along axons. In AD, this transport is impaired due to cytoskeletal dysfunction and tau pathology, reducing BDNF availability at synaptic terminals.
Multiple therapeutic approaches targeting BDNF signaling are being developed for AD:
| Approach | Mechanism | Status |
|----------|-----------|--------|
| BDNF delivery | Exogenous BDNF protein | Preclinical |
| TrkB agonists | Small molecule TrkB activation | Preclinical |
| BDNF mimetics | Peptide mimics of BDNF | Preclinical |
| Gene therapy | AAV-mediated BDNF expression | Phase 1/2 |
| Exercise | Endogenous BDNF elevation | Clinical trials |
Exercise is one of the most effective ways to increase BDNF levels in humans. Aerobic exercise elevates circulating BDNF and promotes neurogenesis in the hippocampus. Regular exercise is associated with reduced AD risk and slower cognitive decline in elderly individuals[@bdnf_exercise_2014].
The dopaminergic neurons of the substantia nigra pars compacta (SNc) are particularly dependent on BDNF for their survival and function. These neurons project to the striatum, forming the nigrostriatal pathway that is critically involved in motor control. BDNF is produced in the striatum and is anterogradely transported to dopaminergic nerve terminals, where it supports neuronal survival and function[@bdnf_pd_2007].
Nigral BDNF decline: Post-mortem studies show reduced BDNF expression in the substantia nigra of PD brains. This reduction likely contributes to the vulnerability of dopaminergic neurons and may represent a therapeutic target.
α-Synuclein interaction: Alpha-synuclein (α-Syn) pathology, the hallmark of PD, interferes with BDNF signaling through multiple mechanisms. α-Syn can impair BDNF trafficking and reduce BDNF expression. Additionally, α-Syn aggregation may sequester BDNF, reducing its availability for signaling.
Therapeutic potential: BDNF gene therapy has shown promise in PD models. Viral delivery of BDNF to the striatum protects dopaminergic neurons from toxin-induced degeneration and improves motor function in animal models[@bdnf_gene_pd_2015].
Beyond direct neuroprotection, BDNF plays important roles in motor circuit function. The basal ganglia motor circuitry requires proper synaptic plasticity for motor learning and motor performance. BDNF-mediated signaling in the striatum is essential for this plasticity, and its dysfunction contributes to motor symptoms in PD.
Motor neurons express high levels of TrkB and are highly dependent on BDNF for their survival. ALS involves progressive degeneration of upper and lower motor neurons, and BDNF signaling dysfunction contributes to this process.
BDNF support: BDNF is produced by skeletal muscle and is retrogradely transported to motor neuron cell bodies, where it supports survival. This trophic support is compromised in ALS due to denervation and muscle atrophy.
Clinical trials: BDNF delivery has been tested in ALS clinical trials. While early trials showed some promise, subsequent studies failed to demonstrate significant clinical benefit. The challenges have been primarily related to delivery—getting sufficient BDNF to the CNS remains difficult.
TrkB signaling preservation: Maintaining TrkB signaling may slow ALS progression. Strategies to enhance TrkB activation or protect TrkB from aggregation are under investigation.
Huntington's disease is characterized by progressive neurodegeneration, particularly in the striatum and cortex. BDNF plays a critical role in this process, as mutant huntingtin protein impairs BDNF production and transport[@bdnf_hd_2008].
BDNF transcription impairment: The mutant huntingtin protein (mHTT) directly impairs BDNF gene transcription. mHTT interferes with the normal function of transcription factors like NRSF (neuron-restrictive silencer factor) and p53, reducing BDNF expression in cortical neurons.
Axonal transport defects: mHTT impairs BDNF axonal transport from the cortex to the striatum. This transport defect means that striatal neurons receive insufficient BDNF support, contributing to their vulnerability.
Therapeutic potential: Enhancing BDNF signaling is a key therapeutic strategy for HD. Approaches include increasing BDNF production, enhancing TrkB signaling, and blocking p75NTR-mediated apoptosis.
The hippocampus is one of the brain regions most affected by BDNF dysfunction in neurodegeneration. The hippocampus is critical for memory formation and spatial navigation, functions that are progressively impaired in AD and other dementias.
BDNF in the hippocampus supports several forms of synaptic plasticity essential for learning and memory. Long-term potentiation (LTP) at hippocampal synapses is a cellular correlate of memory formation, and BDNF is required for LTP induction and maintenance. The PI3K/Akt and MAPK/ERK pathways downstream of TrkB both contribute to LTP.
In Alzheimer's disease, hippocampal BDNF levels are significantly reduced. This reduction correlates with cognitive impairment and may represent both a cause and consequence of synaptic dysfunction. Aβ oligomers directly impair hippocampal BDNF signaling, creating a vicious cycle.
The cerebral cortex is another major site of BDNF dysfunction in neurodegeneration. BDNF supports cortical neuron survival, dendritic arborization, and synaptic connectivity.
In Huntington's disease, cortical BDNF production is specifically impaired due to mutant huntingtin interference with transcription. This leads to reduced BDNF transport to the striatum, contributing to striatal neuron vulnerability.
The substantia nigra pars compacta (SNc) contains dopaminergic neurons that are particularly vulnerable in Parkinson's disease. These neurons require BDNF for survival, and reduced BDNF support contributes to their degeneration.
BDNF is produced in the striatum and is anterogradely transported along axons to dopaminergic nerve terminals. This retrogradely transported BDNF activates TrkB signaling in the cell bodies of SNc neurons, promoting their survival.
In ALS, motor neurons in the spinal cord require BDNF for survival. BDNF is produced by skeletal muscle and is retrogradely transported to motor neuron cell bodies. This trophic support is lost in ALS due to denervation.
BDNF has complex relationships with neuroinflammation, which is a key contributor to neurodegenerative disease progression. The interplay between BDNF and inflammatory processes is bidirectional and context-dependent.
Microglia produce BDNF in response to certain stimuli, contributing to neuroprotection. However, chronic neuroinflammation can impair BDNF signaling and reduce BDNF expression. In AD and PD, neuroinflammatory processes likely contribute to BDNF dysfunction.
Anti-inflammatory treatments may help restore BDNF function. Conversely, strategies that enhance BDNF signaling may reduce neuroinflammation through negative feedback mechanisms.
The inflammatory cytokine IL-1β can suppress BDNF expression in neurons. TNF-α also reduces BDNF expression. These pro-inflammatory effects may contribute to the BDNF reduction observed in neurodegenerative diseases.
BDNF expression shows circadian variation in the brain, with higher levels during the active period. This rhythm is driven by the suprachiasmatic nucleus and is important for daily cognitive function[@bdnf_circadian_2016].
The circadian regulation of BDNF is mediated through the molecular clock machinery. CLOCK and BMAL1 proteins regulate BDNF transcription through E-box elements in the BDNF promoter. This regulation ensures that BDNF signaling is aligned with the sleep-wake cycle.
Circadian disruption, common in neurodegenerative diseases, may contribute to BDNF dysfunction. Sleep disturbances in AD and PD may impair the normal BDNF rhythm, contributing to cognitive and motor symptoms. Restoring circadian rhythm through proper sleep hygiene and timed behaviors may support BDNF function.
BDNF signaling directly affects mitochondrial function, which is relevant given the mitochondrial dysfunction in neurodegenerative diseases.
TrkB activation enhances mitochondrial biogenesis through PGC-1α activation. This effect is mediated through both the PI3K/Akt and MAPK/ERK pathways. Enhanced mitochondrial biogenesis helps neurons meet the high energy demands of synaptic activity.
BDNF also improves mitochondrial dynamics, promoting fission and fusion processes that maintain mitochondrial quality control. In PD, where mitochondrial dysfunction is prominent, BDNF's effects on mitochondrial function may be particularly beneficial.
Exercise is the most effective physiological stimulus for BDNF production. Aerobic exercise increases BDNF expression in the hippocampus and cortex, promotes neurogenesis, and improves cognitive function[@bdnf_exercise_2014].
The mechanisms by which exercise elevates BDNF include:
Recent advances in TrkB agonist development show promise for neurodegenerative diseases. Zhang et al. (2024) identified novel small molecule TrkB agonists that cross the blood-brain barrier and promote neuronal survival in AD and PD models[@trkb_agonist_2024]. These agonists activate TrkB signaling without causing the side effects associated with BDNF itself.
Wang et al. (2023) developed BDNF-loaded exosomes for targeted CNS delivery[@bdnf_exosome_2023]. This approach addresses the delivery challenge by using naturally occurring extracellular vesicles that can cross the blood-brain barrier. The exosomes can be engineered to target specific neuronal populations, providing precise BDNF delivery.
Johnson et al. (2023) demonstrated that TrkB activation promotes amyloid-beta clearance through enhanced microglial phagocytosis[@trkb_brain_2023]. This finding suggests that TrkB agonists could provide dual benefits—directly protecting neurons while also enhancing the brain's natural Aβ clearance mechanisms.
Recent research has uncovered important connections between BDNF, gut microbiota, and neurodegeneration[@bdnf_metabolites_2024]. The gut-brain axis communicates through multiple pathways:
Short-chain fatty acids (SCFAs) produced by gut bacteria can influence BDNF expression in the brain. Butyrate, propionate, and acetate have been shown to enhance BDNF transcription in hippocampal neurons through epigenetic mechanisms.
The vagus nerve provides a direct neural pathway from gut to brain. BDNF signaling in the vagus nerve influences gut motility and may affect bacterial composition, creating bidirectional communication.
Modulating gut microbiota through diet, probiotics, or fecal microbiota transplantation may influence BDNF function and neuroprotection.
The BDNF Val66Met polymorphism (rs6265) has been extensively studied in neurodegenerative diseases[@bdnf_genetics_2024]:
The Met allele has been associated with:
CSF BDNF levels have been investigated as a biomarker for neurodegenerative diseases[@bdnf_csf_2023]:
The BDNF signaling pathway represents a critical therapeutic target for neurodegenerative diseases. Multiple strategies are being developed to enhance BDNF function:
The balance between pro-BDNF/p75NTR signaling and mature BDNF/TrkB signaling is emerging as a key therapeutic target. Shifting this balance toward TrkB signaling may provide neuroprotection across multiple neurodegenerative diseases.
Related Hypotheses: